Associated Papers
Long-term follow-up of combination therapy with pembrolizumab and anlotinib in thoracic SMARCA4-deficient undifferentiated tumor: a case report and molecular features.
Duan T et al.
Frontiers in Oncology, 2024
Select a paper to view details